Rebecca A. Taub M.D.
Net Worth

Last updated:

What is Rebecca A. Taub M.D. net worth?

The estimated net worth of Dr. Rebecca A. Taub M.D. is at least $222,341,668 as of 8 Apr 2024. He owns shares worth $176,714,615 as insider, has earned $39,816,633 from insider trading and has received compensation worth at least $5,810,420 in Madrigal Pharmaceuticals, Inc..

What is the salary of Rebecca A. Taub M.D.?

Dr. Rebecca A. Taub M.D. salary is $830,060 per year as Founder, Chief Medical Officer, Pres of R&D and Director in Madrigal Pharmaceuticals, Inc..

How old is Rebecca A. Taub M.D.?

Dr. Rebecca A. Taub M.D. is 73 years old, born in 1952.

What stocks does Rebecca A. Taub M.D. currently own?

As insider, Dr. Rebecca A. Taub M.D. owns shares in one company:

Company Title Shares Price per share Total value
Madrigal Pharmaceuticals, Inc. (MDGL) Founder, Chief Medical Officer, Pres of R&D and Director 458,999 $385 $176,714,615

What does Madrigal Pharmaceuticals, Inc. do?

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

MDGL logo
MDGL
Madrigal Pharmaceuticals, Inc.
$385

Rebecca A. Taub M.D. insider trading

Madrigal Pharmaceuticals, Inc.

Dr. Rebecca A. Taub M.D. has made 26 insider trades between 2018-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 73,526 units of MDGL stock on 11 Jun 2018. As of 8 Apr 2024 he still owns at least 458,999 units of MDGL stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 2,676 $9.45 $25,288
Option
Common Stock 2,676 $9.45 $25,288
Sale
Common Stock 200 $248.58 $49,716
Sale
Common Stock 407 $247.76 $100,838
Sale
Common Stock 600 $246.98 $148,186
Sale
Common Stock 300 $245.69 $73,706
Sale
Common Stock 945 $244.79 $231,325
Sale
Common Stock 224 $243.25 $54,487
Option
Stock Option (Right to Buy) 27,506 $9.45 $259,932
Option
Common Stock 27,506 $9.45 $259,932
Sale
Common Stock 700 $241.14 $168,799
Sale
Common Stock 5,278 $245.53 $1,295,923
Sale
Common Stock 2,079 $244.45 $508,214
Sale
Common Stock 1,643 $240.11 $394,497
Sale
Common Stock 8,989 $243.33 $2,187,284
Sale
Common Stock 8,817 $242.61 $2,139,066
Sale
Common Stock 3,085 $242.71 $748,763
Sale
Common Stock 4,200 $240.88 $1,011,679
Sale
Common Stock 5,619 $241.85 $1,358,972
Option
Stock Option (Right to Buy) 18,537 $9.45 $175,175
Option
Common Stock 18,537 $9.45 $175,175
Sale
Common Stock 1,653 $246.01 $406,658
Sale
Common Stock 100 $248.23 $24,823
Sale
Common Stock 711 $247.23 $175,778
Sale
Common Stock 2,734 $245.06 $670,005
Sale
Common Stock 435 $244.01 $106,143
Option
Common Stock 27,845 $9.45 $263,135
Sale
Common Stock 4,070 $244.68 $995,856
Sale
Common Stock 2,634 $243.69 $641,866
Sale
Common Stock 135 $242 $32,670
Sale
Common Stock 18,917 $245.34 $4,641,021
Option
Stock Option (Right to Buy) 27,845 $9.45 $263,135
Sale
Common Stock 2,089 $246.33 $514,573
Sale
Common Stock 73,526 $287.46 $21,135,784

Madrigal Pharmaceuticals key executives

Madrigal Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: